ROK
62
15
GE
67
2
TRIP
47
3
AA
48
-12
FSLR
54
7
CSX
60
3
CSCO
67
4
HAS
33
3
EL
25
4
RIG
60
2
CCI
31
3
CTSH
56
2
URBN
56
14
UNP
52
7
HCP
66
8
LLY
37
-3
LRCX
43
-2
EFX
38
2
NWL
53
3
COF
60
2
ROK
62
15
GE
67
2
TRIP
47
3
AA
48
-12
FSLR
54
7
CSX
60
3
CSCO
67
4
HAS
33
3
EL
25
4
RIG
60
2
CCI
31
3
CTSH
56
2
URBN
56
14
UNP
52
7
HCP
66
8
LLY
37
-3
LRCX
43
-2
EFX
38
2
NWL
53
3
COF
60
2
Financhill
Back

Aptevo Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
37

APVO
Aptevo Therapeutics

Last Price:
0.31
Seasonality Move:
-13.9%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Aptevo Therapeutics Price Quote

$0.31
+0.00 (+16.19%)
(Updated: November 23, 2024 at 5:25 AM ET)

Aptevo Therapeutics Key Stats

Sell
37
Aptevo Therapeutics (APVO) is a Sell
Day range:
$0.25 - $0.31
52-week range:
$0.14 - $10.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.07
P/B ratio:
1.29%
Volume:
2M
Avg. volume:
12.5M
1-year change:
-96.32%
Market cap:
$5.7M
Revenue:
$0
EPS:
$-97.25

How Much Does Aptevo Therapeutics Make?

Data Unavailable

Is Aptevo Therapeutics Growing As A Company?

Data Unavailable

Aptevo Therapeutics Stock Price Performance

What Is Aptevo Therapeutics 52-Week High & Low?

Aptevo Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Aptevo Therapeutics?

Is Aptevo Therapeutics Cash Flow Positive?

  • What Is APVO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$23.3M
  • What Is Aptevo Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $11.9M
  • What Is Aptevo Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Aptevo Therapeutics Return On Invested Capital

Data Unavailable

Aptevo Therapeutics Earnings Date & Stock Price

Aptevo Therapeutics Competitors

Aptevo Therapeutics Dividend Yield

Aptevo Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 15.79%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 8.00
Upside from Last Price: 2499.94%

Major Shareholders

  • How many APVO shares are owned by institutional investors?
    1.4M APVO shares are owned by institutional investors
  • How many APVO shares are owned by insiders?
    0 APVO shares are owned by insiders